TABLE 1

Characteristics of patients co-infected with active tuberculosis (TB) and coronavirus disease 2019 (COVID-19)

Patients	Age years	Sex	BMI^#	Comorbidities	TB localisation	Signs and symptoms^¶	PTB pattern at TB diagnosis	Time since TB days^¶	COVID-19 radiological signs^¶	Pulmonary pattern (days from previous CXR/CT scan)^¶	Abnormal biochemistry	O₂ supply
P01	20s	M	L		DS-PTB	Fever, cough, headache	Unilateral cavities^§	20	None^§	Improvement (19)	TLC 770 mm⁻³ Hb 9.9 g·dL⁻¹ CRP 180 mg·L⁻¹ Fer. 623 ng·mL⁻¹ DD 3206 ng·mL⁻¹
P02	60s	M	N	COPD and epilepsy	DS-PTB	Fever	Unilateral nodules^§	84	Minimal signs of interstitial thickening^§	Worsening (15)	No abnormalities	Yes^§§
P03	10s	F	L		DS-PTB	Fever, chest pain, dyspnoea, vomit, conjunctivitis	Bilateral nodules and cavities^§	20	None^§	Worsening (14)	DD 1104 ng·mL⁻¹
P04	20s	M	L		DS-PTB	Fever, cough, vomit	Miliary and cavities^§	14	None^§	Improvement (17)	TLC 980·mm⁻³ Fer. 517 ng·mL⁻¹ DD 2161 ng·mL⁻¹
P05	30s	F	L		DS-PTB	Fever, cough	Bilateral reticules, nodules and cavities^§	302	None^§	Improvement (7)	Fer. 511 ng·mL⁻¹ K⁺ 2.50 mmol·L⁻¹ DD 1179 ng·mL⁻¹	Yes
P06	70s	F	L	Cachexia, chronic vomit and diarrhoea, hypertension, diabetes, mental disorders	DS-PTB	Fever, severe dyspnoea, and respiratory failure	Bilateral nodules and cavities^§, tree in bud^ƒ	26	Interstitial-alveolar thickening^§	Worsening (28)	TLC 920 mm⁻³ K⁺ 2.8 mmol·L⁻¹ DD 5244 ng·mL⁻¹ Fer. unevaluated^##	Yes⁺⁺
P07	30s	M	L		Hr-PTB	Fever, cough	Bilateral cavitary nodules^§	21	None^§	Improvement (34)	TLC 8620 mm⁻³ Fer. 379 ng·mL⁻¹ DD 2516 ng·mL⁻¹
P08	20s	M	N		DS-PTB	Fever, cough	Bilateral nodules and reticules^§	19	None^§	Improvement (31)	No abnormalities	Yes^§§
P09	40s	M	H	Psoriasis and FLD	DS-PTB	Cough, chest pain	Unilateral nodules^§	6	None^§	Improvement (25)	Fer. 978 ng·mL⁻¹
P10	40s	F	H	Diabetes	Hr-PTB⁺	Fever	Bilateral reticules, cavitary nodules^§	8	None^§	Improvement (18)	Fer. 370 ng·mL⁻¹ DD 1029 ng·mL⁻¹
P11	20s	M	L		DS-PTB plus renal, brain, and meningeal TB	Fever, cough, chest pain, headache	Miliary and cavities^§	53	None^§	Worsening (57)	TLC 680 mm⁻³ LDH 283 U·L⁻¹ Fer. 513 ng·mL⁻¹ DD 3065 ng·mL⁻¹ Na⁺ 125 mmol·L⁻¹	Yes^++,ƒƒ
P12	60s	F	N	Diabetes	DS-PTB	Fever	Unilateral thickenings^§	56	None^§	Improvement (32)	No abnormalities
P13	40s	F	L	Anorexia nervosa	DS-PTB plus renal, brain, and meningeal TB	None	Bilateral nodules^§	152	Ground glass^ƒ	Improvement (34)	TLC 720 mm⁻³ Hb 6.1 g·dL⁻¹ CRP 244 mg·L⁻¹ Fer. 768 ng·mL⁻¹	Yes⁺⁺
P14	60s	M	N		DS-PTB plus pericardial, pleural, splenic, and bone TB	None	Bilateral nodules and pleural effusion^§	62	None^§	Worsening (27)	DD 1233 ng·mL⁻¹
P15	30s	M	L		DS-PTB	Cough	Bilateral nodules and cavities^§	97	None^§	Improvement (88)	Fer. 449 ng·mL⁻¹ DD 1657 ng·mL⁻¹ Na⁺ 132 mmol·L⁻¹
P16	40s	M	N	Diabetes	DS-PTB	Fever	Bilateral reticules and nodules^§	43	None^§	Worsening (44)	Fer. 775 ng·mL⁻¹ DD 1492 ng·mL⁻¹
P17	20s	F	N		Hr-PTB	Vomit	Unilateral reticules and nodules^§	38	None^§	Improvement (10)	No abnormalities	Yes^§§
P18	30s	M	N		Pre-XDR-PTB	Cough	Unilateral nodules and cavities^§	30	None^§	Worsening (37)	TLC 1350 mm⁻³ DD 1322
P19	20s	F	L	Sickle cell disease	DS-EPTB: abdominal LN	Chest pain, dyspnoea, vomit	Calcific lesions^§	87	None^§	Unchanged (47)	Hb 8.4 g·dL⁻¹ PLT 9.2×10³ mm⁻³ AST 49 U·L⁻¹ ALT 46 U·L⁻¹ Fer. 5036 ng·mL⁻¹^¶¶
P20	30s	M	N		MDR-PTB (relapse: already treated in 2015)	None	Unilateral thickening^§	40	Interstitial-alveolar thickening^§	Improvement (46)	TLC 1390 mm⁻³ AST 132 U·L⁻¹ ALT 111 U·L⁻¹

^#: body mass index (BMI) was categorised as “low“ (L) if <18.5 kg·m⁻², “normal” (N) if 18.5–25 kg·m⁻², “high” (H) if 25–30 kg·m⁻². ^¶: at COVID-19 diagnosis compared to the last available chest radiograph (CXR) result. ⁺: isoniazid-resistance was detected only through genotypic drug-susceptibility test. ^§: lung pattern at CXR. ^ƒ: lung pattern at chest computed tomography (CT) scan. ^##: ferritin (fer.) was not routinely assessed but was part of a set of exams to perform only in patients affected by COVID-19; however, due to the lag obtaining the swab results for SARS-CoV-2 it was not included. ^¶¶: frequent blood transfusions to treat severe anaemia due to sickle cell disease. ⁺⁺: O₂ supply ex novo. ^§§: O₂ supply at admission and then stopped. ^ƒƒ: O₂ supply was required temporarily due to pleural bleb rupture and consequent pneumothorax. PTB: pulmonary TB; M: male; F: female; FLD: fatty liver disease; DS: drug-susceptible; Hr: isoniazid resistant; XDR: extensively drug resistant; EPTB: extrapulmonary tuberculosis; LN: lymph node; MDR: multidrug-resistant; TLC: total lymphocyte count; Hb: haemoglobin; CRP: C-reactive protein; DD: D-dimer; LDH: lactate dehydrogenase; PLT: platelets; AST: aspartame transaminase; ALT: alanine transaminase.